ARTICLES BY JENNIFER CHAIN
-
![Hard choice or decision-GettyImages-2015287041]( "Why 'Which Is Best?' Is The Wrong Question In CGT Development")
6/27/2025In cell therapy development, the instinct to seek a single “best” option is natural — but in reality, there’s rarely a universal winner.
-
![Man giving blood wearing mask-GettyImages-1340046608]( "A Case For Paying Allogeneic Cell Therapy Product Donors")
5/9/2025The debate over whether to pay donors for cell therapy starting materials comes down to four areas of disagreement: altruism, availability, ethics, and safety.
-
![Unity-GettyImages-491380135]( "Hear Me Out — Cell Therapy GMP Starts With The Donor")
1/9/2025Regulators also have indicated they expect allogeneic cell therapy donors to meet more rigid eligibility requirements and undergo screening.
-
![Sample Storage in test-tube laboratory-GettyImages-638504688]( "Solving The Leukopak Supply Chain Issue With Cryopreservation")
11/25/2024Allogeneic cell therapy developers report an alarming number of starting materials arrive at the wrong temperatures, late, or fail to arrive altogether.
-
![blood bag-GettyImages-2166702483]( "What's In The Leukopak Matters For Cell Therapy Manufacturing")
10/11/2024Advanced cell-based therapies are impossible without high-quality leukopaks from high-quality donors.
Jennifer Chain
Jennifer Chain, Ph.D., CABP, is a cellular therapy expert with 27 years of experience in T-cell immunology, product development, blood banking, and consulting. She holds a Ph.D. in immunology and a Certified Advanced Biotherapies Professional credential from the Association for the Advancement of Blood and Biotherapies (AABB). She currently works as a consultant in the cellular starting material space, helping collection centers and cell therapy companies develop CSM collection and procurement programs and donor screening strategies. Reach her on LinkedIn or CSM Consulting’s website, www.cellsmatter.com.